Single-shot application
Single-shot application has
clear benefits.
Thanks to the cross-linked structure, the intra-articular residence time of Optivisc Single™ is
drastically increased compared to linear low
molecular weight hyaluronic acid formulations.
Allowing for single-shot application.
Travel only once
Wait only once
Less margin for error
One-off costs
Maximum comfort
Less risk of infection
Single-shot application has
clear benefits.
Do you have to go to an outpatient or inpatient clinic or a private doctor’s surgery to get a hyaluronic acid injection, and there isn’t one where you live? Do you need to travel by train or bus, or use a car in justified cases? The Optivisc Single™ injection treatment requires just one intervention, just one visit to a doctor. No need for three or five sessions, and travelling! Just one doctor’s visit!
Save money and time!
Save money and time!
Waiting and queueing!
Even several times?
Optivisc Single™
Save money and time!
Save money and time!
Less margin
for error
There is a potential for error with intra-articular administration, which may increase proportionately when administered on multiple occasions with the number of injections given.
Therapy involving an injection into the joint cavity is not an easy task, requiring excellent manual dexterity and great experience. Nevertheless, the delicate anatomical structures that may be deformed by chronic inflammation can cause unpleasant surprises, even for experienced hands.
The Optivisc Single™ therapy involves a single injection, minimising the risk of error!
The Optivisc Single™ therapy involves a single injection, minimising the risk of error!
Less risk
of infection
There is a risk of infection during intra-articular administration, which may increase proportionately with the number of injections given.
Despite the many advantages of intra-articular products, a major disadvantage is the risk of infection posed by the injection. Apart from adhering to regulations and using sterile components, this can be best avoided by reducing the number of injections administered.
The Optivisc Single™ therapy involves a single injection, minimising the risk of infection!
The Optivisc Single™ therapy involves a single injection, minimising the risk of infection!
Optivisc Single™ is a registered trademark of Biotech Europe Meditech Inc Limited, AF2, IDA Business & Technology Park, Roscommon, Ireland.
Copyright © 2022 SynergoLAB Inc. All rights reserved.
